Document Detail


Heart failure management: the present and the future.
MedLine Citation:
PMID:  19203220     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Clinical heart failure has been defined for a long time as a clinical syndrome with symptoms and signs including shortness of breath, cyanosis, ascites, and edema. However, in recent years, with the thought of promoting early diagnosis and heart-failure prevention, the concept of heart failure has often been defined simply as a subject with severe LV dysfunction and a dilated left ventricle, or by some, defined by evidence of increased circulating levels of molecular markers of cardiac dysfunction, such as ANP and BNP. Heart failure has been considered an irreversible clinical end point. Current medical management for heart failure only relieves symptoms, slows deterioration, and prolongs life modestly. However, in the recent years, rejuvenation of the failing myocardium began to seem possible as the accumulating preclinical studies demonstrated that rejuvenating the myocardium at the molecular and cellular level can be achieved by gene therapy or stem cell transplantation. Here, we review selected novel modalities that have been shown in preclinical studies to exert beneficial effects in animal models of severe LV dysfunction and seem to have the potential to make an impact in the clinical practice of heart-failure management.
Authors:
Mohammad N Jameel; Jianyi Zhang
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Antioxidants & redox signaling     Volume:  11     ISSN:  1557-7716     ISO Abbreviation:  Antioxid. Redox Signal.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-12-01     Completed Date:  2010-02-18     Revised Date:  2013-06-02    
Medline Journal Info:
Nlm Unique ID:  100888899     Medline TA:  Antioxid Redox Signal     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1989-2010     Citation Subset:  IM    
Affiliation:
Department of Cardiology, University of Minnesota, Minneapolis, Minnesota 55455, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Atrial Natriuretic Factor / blood
Genetic Therapy
Heart Failure / blood,  drug therapy,  therapy*
Humans
Natriuretic Peptide, Brain / blood
Grant Support
ID/Acronym/Agency:
HL 67828/HL/NHLBI NIH HHS; HL50470/HL/NHLBI NIH HHS; HL61353/HL/NHLBI NIH HHS; R01 HL050470-13/HL/NHLBI NIH HHS; R01 HL061353-05/HL/NHLBI NIH HHS; R01 HL067828-07/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
114471-18-0/Natriuretic Peptide, Brain; 85637-73-6/Atrial Natriuretic Factor
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Enyne Metathesis/Br??nsted Acid-Promoted Heterocyclization.
Next Document:  Cardiac repair with adult bone marrow-derived cells: the clinical evidence.